Andere talen Entero Therapeutics, Inc.

Aandelen

ENTO

US33749P4081

Vertraagde tijd Nasdaq Andere beurzen 15:48:24 21-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2 ^USD	-3,38%		-3,38%	-52,38%

14/05	First Wave BioPharma, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
29/03	First Wave BioPharma, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Entero Therapeutics : Corporate Presentation (Entero Therapeutics June 2024 Corporate Presentation 2024.6.12 ADA Compliant)	12/06
Entero Therapeutics : Corporate Fact Sheet (Entero Therapeutics Q224 Factsheet 2024.6.7 ADA Compliant 1)	07/06
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention	22/05
Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index	20/05
First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc	17/05
First Wave BioPharma Changes Name to Entero Therapeutics	16/05
First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index	16/05
First Wave BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market	10/05
First Wave BioPharma, Inc. announced a financing transaction	10/05
First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month	09/05
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients	24/04
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase	17/04
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference	15/04
First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference	18/03
Sector Update: Health Care Stocks Retreating Late Afternoon	14/03
Sector Update: Health Care	14/03
First Wave BioPharma Shares Fall After Acquiring ImmunogenX	14/03
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Inflation Data	14/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Entero Therapeutics, Inc.

Aandelen

ENTO

US33749P4081

Andere talen

Filters